Sperm donation research is improving how donors are screened, samples are used, and fertility treatments are selected for people building families with donor sperm. Current studies range from advanced genetic testing to research comparing insemination techniques and treatment timing. Clinical evidence continues to refine reproductive medicine while U.S. regulators and professional organizations maintain detailed safety standards for donor programs.
Current U.S. Standards for Sperm Donor Screening
Sperm donation in the United States operates within established federal safety requirements. The U.S. Food and Drug Administration requires reproductive tissue donors to be screened for medical and behavioral risk factors that could indicate a communicable disease. Donor specimens must also be tested for infections including HIV, hepatitis B, hepatitis C, syphilis, chlamydia, and gonorrhea. Sperm donors require additional testing for human T-lymphotropic virus and cytomegalovirus (source).
The American Society for Reproductive Medicine recommends additional evaluation beyond the federal minimum. Its current guidance addresses genetic screening, medical and family history, semen analysis, and psychoeducational counseling. For nondirected sperm donation, ASRM also recommends genetic screening and requires attention to infectious-disease testing and quarantine procedures (source).
Genetic Research Is Expanding Donor Screening
Genetic screening is one of the most active areas of sperm donation research. A 2025 study examined clinical exome sequencing in 391 sperm donors, analyzing thousands of genes associated with inherited conditions. Researchers found pathogenic or likely pathogenic variants in many participants and ultimately classified 45 donors as unsuitable after additional genetic evaluation (source).
The study was conducted in China, so its screening protocol should not be interpreted as the current U.S. standard. However, it demonstrates how broader genomic testing may reveal inherited risks that family history alone cannot always identify. ASRM currently recommends genetic carrier screening as part of donor evaluation, while more extensive tools such as clinical exome sequencing remain an evolving area of research rather than a universal requirement in U.S. sperm banks (source).
Clinical Trials Have Compared Donor Insemination Methods
Randomized clinical trials have also examined how donor sperm should be used during fertility treatment. One multicenter randomized trial conducted in the Netherlands and Belgium compared intracervical insemination, or ICI, with intrauterine insemination, or IUI, using cryopreserved donor sperm during natural menstrual cycles. The study included 421 participants who were assigned to one of the two treatment approaches (source).
Within eight months, conception resulting in a live birth occurred in 24% of participants assigned to ICI and 39% of those assigned to IUI. Researchers concluded that ICI was less effective than IUI under the conditions studied. Findings from randomized trials like this help clinicians evaluate treatment techniques using live birth outcomes rather than relying only on laboratory measures or theoretical advantages (source).
Researchers Are Studying the Best Timing for IUI
Another area of investigation is the timing of donor-sperm insemination. A 2024 study examined 1,170 natural-cycle donor insemination treatments to compare IUI performed shortly after a spontaneous luteinizing hormone surge with insemination performed after ultrasound confirmation of ovulation. Overall clinical pregnancy and live birth rates were not significantly different between the two groups (source).
Research into timing matters because frozen donor sperm is a limited resource within each treatment cycle, making careful scheduling an important part of fertility care. The 2024 study was observational rather than a randomized clinical trial, so its findings do not establish one universal timing strategy. Instead, the results add evidence clinicians can consider alongside individual reproductive factors and treatment protocols.
New Research Is Examining Whether Changing Donors Matters
Researchers are also investigating questions that commonly arise after unsuccessful insemination attempts. A 2025 retrospective study followed 312 women receiving donor-sperm IUI and examined whether switching sperm donors after unsuccessful cycles affected the number of additional attempts needed to achieve pregnancy. The researchers found an association between changing donors and fewer additional cycles to pregnancy after the switch, while acknowledging that prospective research is still needed (source).
The findings raise interesting questions about whether biological compatibility between a particular donor's sperm and a recipient's reproductive system could influence treatment success. However, the study does not prove that changing donors causes better outcomes, and it should not be interpreted as a recommendation to automatically switch donors after a certain number of unsuccessful attempts. Larger prospective studies could provide clearer answers.
Treatment Outcomes Depend on More Than the Sperm Donor
Research consistently shows that donor sperm is only one part of the fertility-treatment equation. A large 2024 cohort study examined more than 10,000 IUI cycles involving donor or partner sperm and found that cumulative live birth rates declined substantially with increasing recipient age. Among patients using donor sperm, younger age groups experienced considerably higher cumulative live birth rates than patients approaching or exceeding age 40 (source).
Factors such as age, ovarian reserve, ovulation, reproductive anatomy, treatment method, and underlying medical conditions can all affect the likelihood of pregnancy. Donor screening is designed to address infectious and genetic risks, but it cannot guarantee a particular fertility outcome. Clinical research helps specialists understand how donor-related factors interact with the health and reproductive characteristics of the person receiving treatment.
Where Sperm Donation Research Is Heading
Modern sperm donation research extends well beyond simply measuring sperm count or motility. Scientists are investigating broader genetic screening, comparing insemination methods, examining treatment timing, and studying why some donor-recipient combinations may succeed after others do not. At the same time, FDA requirements and ASRM recommendations provide an established framework for donor safety in the United States.
Some of the strongest evidence comes from randomized clinical trials, while newer questions are often being explored through cohort and retrospective studies before larger trials are available. For people considering donor-assisted reproduction, current research offers increasingly detailed information, but individual treatment decisions still depend on medical history, fertility evaluation, and guidance from a qualified reproductive healthcare professional.